UCB
As of the edition of 20 October 2026, UCB runs 62 drugs, 37 of them marketed; it is on route A at 7 targets and on route B at 18 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 15 company names in this family.
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.: acquired in 2022; successor RA PHARMACEUTICALS, INC.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 37 |
| Active | 7 |
| Went quiet | 4 |
| Stopped | 8 |
| Status not established | 6 |
| Total | 62 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dexamethasone | none listed | 5 |
| Midazolam | none listed | 1 |
| Hydrocortisone | none listed | 5 |
| Levetiracetam | none listed | 3 |
| Lacosamide | Ended 2026 (exclusivity) | 0 |
| Certolizumab pegol | Ended 2020 (computed from the first US licence) | 1 |
| Famotidine | none listed | 2 |
| Metoclopramide | none listed | 3 |
| Rotigotine | none listed | 5 |
| Baclofen | none listed | 1 |
| Cetirizine | none listed | 3 |
| Sumatriptan | none listed | 1 |
| Hydrocodone | none listed | 9 |
| Alprazolam | none listed | 1 |
| Levocetirizine | none listed | 1 |
| Bimekizumab | Ends 2035 (computed from the first US licence) | 2 |
| Pseudoephedrine | none listed | 4 |
| Brivaracetam | Ended 2026 (patent) | 1 |
| Oxybate | Ends 2028 (exclusivity) | 2 |
| Dexamethasone phosphoric acid | none listed | 2 |
| Phentermine | none listed | 0 |
| Romosozumab | Ends 2031 (computed from the first US licence) | 2 |
| Alprostadil | none listed | 2 |
| Isosorbide mononitrate | none listed | 4 |
| Fenfluramine | Ends 2036 (patent) | 3 |
A route B row is one company at one target. 12 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 7 targets, route B at 18 targets.
All 25 rows on route A or B
In the product25 company-target rows on route A or B; 22 are not shown here, and no score is.
See all 25 targets where UCB needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 58 trials led
- Immune system: 35 trials led
- Skin and connective tissue: 35 trials led